Particle.news
Download on the App Store
10 ARTICLES
·
last wk.

New Oral Antibiotic Gepotidacin Confirmed Effective for Drug-Resistant Gonorrhoea

Phase three trials show gepotidacin matches standard treatments and targets resistant strains, with FDA submission expected soon.

Neisseria gonorrhoeae
Image
Image

Overview

  • Gepotidacin, the first new antibiotic for gonorrhoea since the 1990s, has been validated through phase three clinical trials.
  • The study found gepotidacin to be as effective as the current standard injectable treatment, ceftriaxone with azithromycin, in 622 patients.
  • The oral pill successfully treats ceftriaxone-resistant and extensively drug-resistant (XDR) strains of gonorrhoea.
  • Gepotidacin offers a patient-friendly oral treatment option, potentially improving healthcare efficiency and reducing reliance on injections.
  • GlaxoSmithKline plans to submit the drug for FDA approval in the coming months, aiming to provide an alternative for cases where standard treatments are unsuitable.